###### Key messages

-   Approximately 50% of middle-aged individuals with cardiovascular risk factors presenting with atypical chest pain will have previously undiagnosed coronary artery disease (CAD); presence of diabetes history does not affect this relationship.

-   Patients with diabetes mellitus (DM) showed more affected coronary segments and more obstructive CAD than patients without DM.

-   Obstructive CAD was detected more frequently in women with DM, as compared with men with DM.

-   Duration of DM (\>5 years) is associated with the occurrence of distal plaques.

Introduction {#s1}
============

The number of people with diabetes mellitus (DM) is increasing due to population growth, aging, urbanization, increasing prevalence of obesity, and physical inactivity, with an estimated number of 200 million patients worldwide.[@R1] Patients with DM have a twofold to fourfold likelihood of developing coronary artery disease (CAD) with marked morbidity and mortality.[@R2] CAD in patients with DM is often more advanced at the time of diagnosis compared with patients without DM.[@R3] [@R4]

Non-invasive cardiac imaging for the detection of CAD has evolved rapidly in the past decades. Coronary CT angiography (CCTA) offers detailed information on the extent and morphology of CAD. CCTA combined with coronary calcium scoring (CAC-score) is sensitive and specific in the detection of CAD and has been validated extensively.[@R5] The real strength of CCTA is the exclusion of CAD in patients with a low-to-intermediate cardiovascular risk profile, and for this particular indication, there is a broad endorsement from international societies.[@R6] Owing to technological improvements of CCTA, the radiation dose per patient has been reduced to acceptable levels. The latest generation scanners produce submillisievert (mSv) scans without compromising image quality.[@R7]

The aim of the present study was to compare characteristics of CAD in patients with atypical chest pain with and without DM using a CCTA scanner of the latest generation, and to investigate the relationship between CAD and the duration of DM.

Methods {#s2}
=======

Study design {#s2a}
------------

Consecutive patients with atypical chest pain, referred for CCTA to exclude CAD at the Medical Center Alkmaar (MCA) were entered in a database prospectively between December 13, 2011 and March 08, 2013. Patients were categorized in two groups, either with or without known DM. Type 1 and 2 DM were included. DM was diagnosed according to the American Diabetes Association criteria: fasting glucose level of ≥7 mmol/L, symptoms of DM and casual plasma glucose of ≥11.1 mmol/L, or the need for oral hypoglycemic agents or insulin.[@R8] Only patients in sinus rhythm and without contraindications to CCTA were included. Other exclusion criteria were a history of CAD, myocardial infarction (MI), and/or revascularization procedures. All patients gave written informed consent.

The following patient characteristics were recorded: general data such as age and gender, a full cardiovascular risk profile, active medication use, Duke risk score calculation,[@R9] and the Diamond-Forrester risk score calculation.[@R10] Positive family history of premature CAD was defined as the presence of CAD in first-degree relatives younger than 55 (men) or 65 (women) years of age.[@R11] Smoking was defined as nicotine misuse within the previous 5 years. Hypertension was defined as a systolic blood pressure above 140 mm Hg and/or a diastolic blood pressure above 90 mm Hg or the use of antihypertensive drugs.[@R12] High cholesterol was defined as a total cholesterol \>5.0 mmol/L or the use of lipid-lowering therapy.[@R13] The duration of DM was categorized in two groups (\<5; \>5 years). Furthermore, differences between women and men were analyzed.

Patient preparation {#s2b}
-------------------

CCTA was performed under fasting conditions. Medication could be used normally, with the exception of metformin (in case estimated glomerular filtration rate (eGFR) \<60 mL/min) and sildenafil. To prevent contrast-induced nephropathy, patients with an eGFR between 30 and 60 mL/min received volume expansion therapy, using 0.9% NaCl intravenously, before and after CCTA according to the local hospital safety protocol. In case of a heart rate above 60 bpm, 100 mg atenolol was given orally 1 h prior to the CCTA. Additionally, up to 30 mg metoprolol was administered intravenously to decrease the heart rate if the heart rate still exceeded 60 bpm. Each patient also received two doses of 0.4 mg nitroglycerin sublingually.

CAC-score and CCTA data acquisition {#s2c}
-----------------------------------

All scans were performed with a dual source 128--slice (Somatom Definition Flash; Siemens Medical Systems, Erlangen, Germany). A 10--15 mL test bolus containing non-ionic low-osmolar iodinated radiocontrast (iopromide) was injected, followed by a flush of 40 mL saline, both at a flow rate of 6 mL/s. The time point of maximal contrast enhancement in the ascending aorta at the level of the pulmonary trunk was recorded, and an additional delay of 5 s was added to define the optimal time point for acquisition of coronary artery data. A dual-head injector then injected 48--75 mL contrast depending on kV used for the high-pitch flash scan and 75 mL in case of prospective or retrospectively triggered scan, followed by 45 mL 30/70% contrast/saline solution at a flow rate of 6 mL/s.

The tube voltage (80, 100, or 120 kV) and tube current were determined automatically by the scanning system based on body geometry.[@R14] In this study, the total radiation dose of test bolus, topogram, CAC-score, and CCTA was used to estimate the effective radiation dose for each patient.

CAC-score and CCTA image analysis {#s2d}
---------------------------------

All scans were read by two physicians, who are level 2 accredited by the Society of Computed Cardiovascular Tomography (SCCT).

For CAC-score, coronary calcifications were defined as dense lesions in coronary arteries with densities \>130 Hounsfield units. Calcifications were manually assigned to coronary arteries and added to the Agatston score for each patient.[@R15] Agatston scores were divided into three groups: a CAC-score between 0--100, 101--400, and more than 400.

Plaque characteristics were compared on a per patient and segment basis. Coronary arteries were divided into 18 segments according to the SCCT guidelines.[@R16] Each segment was scored for the presence of coronary plaques. Structures \>1 mm^2^ within and/or adjacent to the coronary artery lumen, which could be clearly distinguished from the vessel lumen, were scored as a coronary plaque.[@R17] One coronary plaque was scored per coronary segment. Each coronary plaque was quantified for stenosis by visual estimation. The severity of stenosis was categorized (\<25%; 25--49%; 50--69%; 70--99%; 100%). A stenosis of \>50% was considered to be obstructive. The number of coronary segments with non-obstructive as well as obstructive plaques was determined for each patient. The morphology of a coronary plaque was categorized as calcified, non-calcified, or mixed lesion.

CAD was determined as CAC-score \>0 and/or any coronary plaque. CAC-score=0 and no coronary plaques was defined as no CAD.

To compare the distribution of coronary plaques between patients with and without DM, patients were stratified by the location/distribution of atherosclerosis in either proximal or distal segments. The left main artery and proximal segments of the left anterior descending (LAD), right coronary artery (RCA), and ramus circumflexus (RCX) were assigned to the proximal group. Mid and distal segments of LAD, RCA, and RCX and all evaluable other coronary branches were assigned to the distal group.

Statistical analysis {#s2e}
--------------------

Continuous variables are presented as mean±SD and categorical variables as frequencies with percentages. One-sample Kolmogorov-Smirnov tests were used to test continuous data for normal distribution. Between groups, differences in mean values were tested for statistical differences with two-sample t tests and Mann-Whitney tests, when appropriate. Pearson χ^2^ tests were used to test dichotomous parameters. To determine the relationship between plaque characteristics and DM, logistic regression analyses were performed when the dependent variable was dichotomous. When the dependent variable was continuous, linear regression analyses were performed. Univariate analyses were performed using demographic variables, classical risk factors, risk scoring systems, and medication used (variables specified in [table 1](#BMJDRC2013000004TB1){ref-type="table"}). Multivariable analyses were performed with variables that were significant in univariate analyses. p Values \<0.05 were considered significant. The Duke risk score was not analyzed in the univariate and multivariate analyses because DM is one of the parameters in this particular score. The Diamond-Forrester score, not using DM as a parameter, was used instead. For the detailed per segment analysis, the unit of measure was each coronary segment and there were no adjustments or corrections made for the serial correlation between segments. Statistical Package for Social Sciences V.20 (SPSS Inc, Chicago, Illinois, USA) was used.

###### 

Baseline, CAC-score and CCTA characteristics of study population with and without DM

  Variable                                           DM (n=99)    Non-DM (n=1049)   p Value
  -------------------------------------------------- ------------ ----------------- ---------
  Demographic                                                                       
   Age (years)                                       58.6±9.9     57.7±10.8         0.435
   Sex (% male)                                      64 (64.6)    663 (63.2)        0.776
   Duration of DM (years)                            6.6±6.9      0±0               
  Risk factors                                                                      
   Hypertension                                      73 (73.7)    676 (64.4)        0.063
   Dyslipidemia                                      86 (86.9)    823 (78.5)        0.049
   Obesity (BMI ≥30)                                 43 (43.4)    188 (17.9)        0.001
   Smoking                                           19 (19.2)    213 (20.3)        0.792
   Family history of CAD                             53 (53.5)    518 (49.4)        0.429
  SBP (mm Hg)                                        138.8±17.4   133.1±17.2        0.678
  DBP(mm Hg)                                         81.2±12.4    80.7±11.5         0.833
  LDL cholesterol (mmol/L)                           2.9±1.1      3.6±1.0           0.770
  HDL cholesterol (mmol/L)                           1.2±0.3      1.4±0.4           0.003
  Total cholesterol(mmol/L)                          4.9±1.4      5.7±1.1           0.060
  HbA1c (mmol/L)                                     7.2±1.1      5.7±0.4           0.001
  Duke score                                                                        
   Low risk                                          36 (36.4)    599 (57.1)        0.001
   Intermediate risk                                 56 (56.5)    425 (40.5)        0.002
   High risk                                         7 (7.1)      26 (2.4)          0.007
  Diamond-Forrester score                            39.5±21.6    38.2±22.2         0.562
  Medication                                                                        
   ACE-I/ARB                                         43 (43.4)    238 (22.7)        0.001
   Aspirin                                           41 (41.4)    357 (34.0)        0.140
   β-blocker                                         52 (52.5)    437 (41.7)        0.037
   Statin                                            64 (64.6)    345 (32.9)        0.001
  Technical data                                                                    
   Heart rate (bpm)                                  61.0±7.4     57.1±7.0          0.001
   Radiation dose (mSv)                              3.8±2.7      2.2±1.8           0.001
  CCTA                                                                              
   CAC-score                                         118±270.7    73.5±209.3        0.049
    0--100                                           74 (74.7)    866 (82.6)        0.057
    101--400                                         19 (19.2)    125 (11.9)        0.037
    \>400                                            6 (6.1)      58 (5.5)          0.826
   Normal/no plaque                                  46 (46.5)    515 (49.1)        0.617
   CAD                                               53 (53.5)    534 (50.9)        0.674
   Obstructive CAD                                   23 (23.2)    121 (11.5)        0.001
   Non-obstructive CAD                               30 (30.3)    413 (39.4)        0.076
  Segments                                                                          
   Number of diseased segments                       2.5±3.4      1.7±2.4           0.003
   Number of segments with obstructive plaques       0.4±1.0      0.2±0.6           0.001
   Number of segments with non-obstructive plaques   2.0±2.8      1.5±2.1           0.022
   Number of diseased segments LM                    0.2±0.4      0.1±0.3           0.114
   Number of diseased segments RCA                   0.7±1.1      0.4±0.8           0.008
   Number of diseased segments LAD                   1.1±1.4      0.8±1.1           0.053
   Number of diseased segments RCX                   0.6±1.0      0.3±0.7           0.001

Categorical variables are expressed as count (%). Continuous variables are expressed as mean±SD.

ARB, angiotensin receptor blocker; BMI, body mass index; CAC-score, coronary calcium score; CAD, coronary artery disease; CCTA, cardiac CT coronary angiography; DBP, diastolic blood pressure; DM, diabetes mellitus; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LAD, left anterior descending; LDL, low-density lipoprotein; LM, left main; mSv, millisievert; RCA, right coronary artery; RCX, ramus circumflexus; SBP, systolic blood pressure.

Results {#s3}
=======

Study population {#s3a}
----------------

A total of 1176 patients with atypical chest pain were enrolled in the study, of which 28 patients were excluded. Twenty-three patients were excluded due to a history of CAD, MI, and/or revascularization procedures. Five patients suffered from arrhythmias during scan acquisition which resulted in unacceptable image quality, and thus, these patients were excluded. [Table 1](#BMJDRC2013000004TB1){ref-type="table"} summarizes the characteristics of patients with and without DM at the time of the CCTA. In total, 1148 patients (727 (63.3%) men; age (mean 57.7 years±10.7)) were included, of whom 99 (8.6%) were patients with known DM (mean 6.6 years±6.9). Of the study population, 95.4% had a low-to-intermediate probability for CAD according to their Duke risk score (92.9% DM vs 97.9% non-DM, p=0.007). Patients with DM were more frequently obese and used more ACE-I/angiotensin receptor blocker, β-blocker, and statin therapy and had lower high-density lipoprotein levels (p values 0.001, 0.001, 0.037, 0.001, and 0.003, respectively). [Table 2](#BMJDRC2013000004TB2){ref-type="table"} compares the clinical and radiographic characteristics of patients with DM who did or did not have CAD. Patients with DM without CAD were more often of the male gender, showed less frequent dyslipidemia, and used less statin therapy (p values 0.020, 0.018, and 0.046, respectively). None of the other measured clinical variables differed between patients with DM with or without CAD.

###### 

Baseline characteristics of patients with DM with and without CAD

  Variable                  DM with CAD (n=53)   DM without CAD (n=46)   p Value
  ------------------------- -------------------- ----------------------- ---------
  Demographic                                                            
   Age (years)              62.1±9.2             54.5±9.2                0.718
   Sex (% male)             29 (54.7)            35 (76.1)               0.027
   Duration of DM (years)   7.1±7.4              6.0±6.3                 0.468
  Risk factors                                                           
   Hypertension             29 (54.7)            17 (37.0)               0.077
   Dyslipidemia             50 (94.3)            36 (78.3)               0.018
   Obesity (BMI ≥30)        20 (37.7)            20 (43.5)               0.220
   Smoking                  8 (15.1)             11 (23.9)               0.266
   Family history of CAD    28 (52.8)            25 (54.3)               0.880
  Medication                                                             
   ACE-I/ARB                28 (52.8)            15 (32.6)               0.043
   Aspirin                  26 (49.1)            15 (32.6)               0.098
   β-blocker                30 (56.6)            22 (47.8)               0.383
   Statin                   39 (73.6)            25 (54.3)               0.046
  Technical data                                                         
   Heart rate (bpm)         59.3±6.6             62.7±8.0                0.849
   Radiation dose (mSv)     3.6±2.9              4.0±2.6                 0.640

Categorical variables are expressed as count (%). Continuous variables are expressed as mean±SD.

ARB, angiotensin receptor blocker; BMI, body mass index; CAD, coronary artery disease; DM, diabetes mellitus; mSv, millisievert.

CAD on CCTA {#s3b}
-----------

Coronary plaque characteristics on CCTA in patients with and without DM are shown in [table 1](#BMJDRC2013000004TB1){ref-type="table"}. A normal CCTA was found in 561 (48.9%) patients, with no significant difference in prevalence between patients with and without DM (p=0.617). Patients with DM had a significantly higher CAC-score than patients without DM (118±270 vs 73±209, p=0.049). Patients with DM had a significantly higher percentage of CAC-scores between 101 and 400 (19% vs 11.9%, p=0.037). Obstructive CAD was observed in 144 (12.5%) patients and more frequently in patients with DM (23.2% vs 11.5%, p\<0.001). Higher CAC-scores were detected in patients with obstructive CAD (287.3±332.9 vs 47.2±173.4, p\<0.001). The average number of diseased segments was higher in patients with DM compared with patients without DM (p=0.003). The number of segments with obstructive CAD plaques was higher in patients with DM compared with patients without DM. In patients with DM, the average number of diseased segments in the RCA (p=0.008) and RCX (p\<0.001) was higher than in patients without DM. The difference in the average amount of diseased segments in the LAD did not reach statistical significance (p=0.053).

[Figure 1](#BMJDRC2013000004F1){ref-type="fig"} shows the prevalence of obstructive CAD across the subgroup gender. Women had an overall higher prevalence of obstructive CAD than men. In patients with DM, 40% of the women demonstrated obstructive CAD compared with 14.1% of the men (p=0.003). In patients without DM, 16.8% of the women compared with 8.4% of the men showed obstructive CAD (p\<0.001).

![Prevalence of obstructive coronary artery disease (CAD) across the different diabetes mellitus and gender subgroups.](bmjdrc2013000004f01){#BMJDRC2013000004F1}

Relationship of CAD characteristics on CCTA and DM {#s3c}
--------------------------------------------------

The results of the univariate and mulitivariate analyses of the correlation between plaque characteristics on CCTA and the presence of DM are listed in [table 3](#BMJDRC2013000004TB3){ref-type="table"}. After correction for baseline characteristics, DM proved to be an independent predictor of the total number of segments with plaque (p=0.016). The other independent predictors of the total number of segments with plaque were age (p\<0.001), women (p\<0.001), Diamond-Forrester score (p\<0.001), and hypertension (p=0.023). Furthermore, DM was an independent predictor of the presence of obstructive plaque (OR 2.16, 95% CI 1.23 to 3.78), as were age (OR 1.04; 95% CI 1.02 to 1.07), women (OR 4.95; 95% CI 2.96 to 8.28), and Diamond-Forrester score (OR 1.02; 95% CI 1.00 to 1.03). DM was also an independent predictor of the number of segments with plaque in the distal segments (p=0.010), as were age (p\<0.001), women (p\<0.001), and Diamond-Forrester score (p=0.008).

###### 

Estimates of correlation of CCTA plaque characteristics with the presence of DM

  Variable                     Univariate, parameter estimate   p Value   Multivariate, parameter estimate   p Value
  ---------------------------- -------------------------------- --------- ---------------------------------- ---------
  Total calcium score          22.25                            0.049     16.88                              0.127
  Total segments with plaque   0.394                            0.003     0.292                              0.016
  CAD                          1.11 (0.74 to 1.70)              0.617                                        
  Obstructive plaque           2.32 (1.40 to 3.84)              0.001     2.16 (1.23 to 3.78)                0.007
  Non-obstructive plaque       0.67 (0.43 to 1.05)              0.078                                        
  LM (yes or no)               1.54 (0.90 to 2.70)              0.107                                        
  RCA (yes or no)              1.45 (0.93 to 2.60)              0.101                                        
  LAD (yes or no)              1.22 (0.81 to 1.85)              0.337                                        
  RCX (yes or no)              1.59 (1.01 to 2.49)              0.044     1.36 (0.82 to 2.26)                0.229
  Proximal plaques             0.142                            0.019     0.089                              0.110
  Distal plaques               0.253                            0.002     0.203                              0.010

Data are ORs (95% CI) or estimates of correlation.

CAD, coronary artery disease; CCTA, cardiac CT coronary angiography; DM, diabetes mellitus; LAD, left anterior descending; LM, left main; RCA, right coronary artery; RCX, ramus circumflexus.

Per segment analysis {#s3d}
--------------------

A total of 17 240 segments were identified in the study population. After exclusion of 105 (0.61%) segments due to non-diagnostic image quality, a total of 17 135 coronary segments were included in the analysis. In the remaining 17 135 segments, 1998 (11.7%) segments contained plaque. Of the 17 135 segments, there were 243 (1.4%) segments with obstructive plaque, (44 of 1471 (3.0%) segments in patients with DM, 199 of 15 664 (1.3%) in patients without DM, p\<0.001).

Accordingly, the distribution of plaque types differed between DM and non-DM: mixed plaques (13.3% vs 9.2%, p\<0.001), calcified plaques (2.0% vs 1.3%, p=0.015), and non-calcified plaques (1.4% vs 0.8%, p=0.023). Patients with DM showed significantly more affected segments than patients without DM in the RCA (4.4% vs 2.7%, p\<0.001), LAD (7.3% vs 5.6%, p=0.012), and RCX (3.8% vs 2.1%, p\<0.001).

Subgroup analysis for duration of DM {#s3e}
------------------------------------

[Table 4](#BMJDRC2013000004TB4){ref-type="table"} shows the subgroup analysis for duration of DM in the per segment analysis. Duration of DM was categorized into two groups (\<5; \>5 years). Although patients suffering from DM for more than 5 years had a higher percentage of involvement of the distal segments (11.2% vs 7.8%, p=0.030), duration of diabetes had minimal impact on total number of segments with plaque, number of obstructive lesions, and morphology of plaques.

###### 

Prevalence, extent, localization, and morphology of plaques---per segment analysis in subgroup duration of DM

                               DM \<5 years (n=53; 797 segments)   DM \>5 years (n=46; 683 segments)   p Value
  ---------------------------- ----------------------------------- ----------------------------------- ---------
  Total segments               790 (99.1)                          681 (99.7)                          0.149
  Total segments with plaque   121 (15.3)                          125 (18.4)                          0.108
  Obstructive plaque           23 (2.9)                            21 (3.1)                            0.847
  Non-obstructive plaque       98 (12.4)                           104 (15.3)                          0.111
  Plaque in LM                 12 (1.5)                            6 (0.9)                             0.267
  Plaque in RCA                32 (4.1)                            32 (4.7)                            0.544
  Plaque in LAD                53 (6.7)                            55 (8.1)                            0.316
  Plaque in RCX                24 (3.0)                            32 (4.7)                            0.097
  Proximal plaque              59 (7.5)                            49 (7.2)                            0.841
  Distal plaque                62 (7.8)                            76 (11.2)                           0.030
  Mixed plaque                 96 (12.2)                           99 (14.5)                           0.179
  Calcified plaque             15 (1.9)                            15 (2.2)                            0.681
  Non-calcified plaque         10 (1.3)                            11 (1.6)                            0.573

Categorical variables are expressed as count (%).

DM, diabetes mellitus; LAD, left anterior descending; LM, left main; RCA, right coronary artery; RCX, ramus circumflexus.

Discussion {#s4}
==========

In the present study, differences in characteristics of CAD between patients with and without DM were detected by means of CCTA. A significant, positive correlation between the presence of DM and total number of segments with plaque was demonstrated. Patients with DM had a significantly higher percentage of obstructive plaques, and this was particularly true for women. Patients suffering from DM for more than 5 years did not demonstrate more obstructive coronary disease or different plaque morphology, although more distal disease was present.

Extent of CAD {#s4a}
-------------

The present study showed a positive correlation between the presence of DM and the total number of segments with plaque. Patients with DM showed more affected segments than patients without DM. Higher prevalence of plaques in patients with DM has been reported in previous invasive as well as postmortem studies. Pundziute *et al*[@R18] reported observations in 60 patients (including 19 with DM) using CCTA followed by conventional coronary angiography with intravascular ultrasound (IVUS); the authors demonstrated that patients with DM had significantly more affected segments on CCTA and with IVUS. In a postmortem study, Burke *et al*[@R19] showed that patients with DM have a larger amount of total and distal plaques. In our study, in patients with atypical chest pain, DM was also associated with more obstructive CAD. This is in line with an earlier study performed by Chu *et al*[@R20] who demonstrated more obstructive plaques in symptomatic patients with DM as compared with patients without DM (2.5±2.5 vs 1.1±1.4). The CAC-score in our study was higher in patients with DM, compared with patients without DM (118±270.7 vs 73.5±209.3, p=0.049). This is in line with an earlier study by de Araujo *et al*[@R21], who showed a significant difference in (median) CAC-score between patients with atypical chest pain with and without DM (68(0--311) vs 0 (0--67), p\<0.001). While our study looked at CAD in patients with atypical chest pain and DM, several studies have demonstrated CAD in asymptomatic patients with DM. Scholte *et al*[@R22] revealed a high prevalence of CAD in asymptomatic patients with type 2 DM, with almost 80% showing CAD. Zeina *et al* also showed a higher prevalence of CAD in asymptomatic patients with DM. The total CAC-score was significantly higher in patients with DM than in patients without DM (p\<0.001). Higher CAC-scores were present in patients with obstructive CAD.[@R23] In an earlier study, Rivera *et al*[@R24] also demonstrated an increasing prevalence of significant stenoses with increasing CAC-scores (p\<0.001).

The present study showed that many patients with DM already developed serious CAD at the time of examination. One explanation could be that DM had existed long before it was diagnosed, due to lack of typical symptoms of the disease, and cardiovascular damage could have developed meanwhile.[@R4] The previously mentioned studies demonstrated this in asymptomatic patients with DM.

Furthermore, in the present study women had a higher percentage of obstructive CAD in the DM and non-DM group. This is in contrast with several previous studies with CCTA that showed more obstructive CAD in men.[@R21] [@R25] These apparently conflicting results might be explained by the increasing notion of, and attention to, the atypical and late presentation of cardiac symptoms in women.[@R26] [@R27] On average, clinical symptoms of heart disease appear 10 years later in women than in men.[@R26] Studies in the Women\'s Ischemia Syndrome Evaluation (WISE) study support the concept of a multifactorial model where sex hormones interact with traditional and novel risk factors. Especially inflammatory process biomarkers (such as C reactive protein), leading to an increase in the functional expression of atherosclerotic plaque and vascular or metabolic alterations result in worse outcomes for women.[@R28] Also, medical diagnosis and treatment for stable angina is different in men and women.[@R29] Women were less likely to be referred for testing, in particular for exercise testing and invasive angiography. Antiplatelet and statin therapies were used significantly less in women than in men at the initial assessment and at 1 year, even in those in whom CAD had been confirmed, which unfortunately influences outcome.

Duration of DM {#s4b}
--------------

Previous studies have shown that the duration of type 2 DM correlates with all-cause mortality and significantly increases cardiovascular mortality.[@R30] [@R31] An autopsy study demonstrated an association between DM duration and the extent of atherosclerosis and myocardial lesions.[@R32] Clarkson *et al*[@R33] showed that vascular reactivity, a marker of impaired endothelial dysfunction, is impaired in patients with long-term type 1 DM. Also the degree of impairment is related to the duration of DM. Thus, one may speculate that longer exposure to hyperglycemia may increase the risk of endothelial dysfunction and thus increase the risk of developing CAD. To the best of our knowledge, no studies researched the correlation between the duration of DM and distal plaques. In our study, we found that patients suffering from DM for more than 5 years have more distal plaques, although they did not demonstrate more obstructive coronary disease or different plaque morphology. Patients suffering from DM for a prolonged period will have more extensive and widespread disease.

Radiation dose CCTA {#s4c}
-------------------

Bell *et al*[@R34] showed in a prospective study that iodinated contrast, β-blockers, and nitroglycerin as part of a predefined CCTA protocol are safe and associated with a low rate of adverse events. In the past decade, studies have focused on radiation dose-reduction techniques with CCTA. The latest generation CCTA scanners can provide an effective dose below 1.0 mSv.[@R7] In comparison, patient dose is typically 2.4 mSv for a ^13^NH~3~ positron emission tomography scan, 2.5--5 mSv for diagnostic invasive selective coronary angiography, and 5--16 mSv for nuclear myocardial perfusion imaging by means of single photon emission CT.[@R35] Safety and low radiation exposure with a high negative predictive value makes CCTA a very appropriate imaging technique for the exclusion of CAD in symptomatic patients and perhaps even as a presymptomatic screening tool. The radiation dose of CCTA in this study is higher in patients with DM compared with patients without DM. This difference could be explained by the fact that patients with DM are more obese compared with patients without DM. Obese patients require a higher tube voltage (kV) and current (mAs) to produce a diagnostic CCTA, which leads to a higher radiation dose.

Clinical implication {#s4d}
--------------------

The combination of CAD and DM strongly increases cardiovascular mortality.[@R30] [@R31] The present study showed that a clinically significant number of patients with atypical chest pain and DM already had developed (serious) CAD at the time of first examination. Previous studies with asymptomatic patients also demonstrated a higher prevalence (80--93%) of CAD in patients with DM.[@R22] There is extensive evidence of prognostic information using CAC-score in symptomatic and asymptomatic patients.[@R38] However, the additional value of performing CCTA in these patients has been a matter of debate. In the CONFIRM registry, CCTA was unable to predict death of non-fatal MI in 7500 patients.[@R39] Nonetheless, in symptomatic patients the incremental prognostic value of CCTA has been established.[@R40] The best CCTA parameter for prediction of mortality was the number of proximal segments with mixed or calcified plaques.[@R41] Thus, CCTA is useful in detection of CAD in patients with DM, either with or without symptoms of atypical chest pain. The high diagnostic yield in symptomatic patients with DM may justify the use of CCTA in daily clinical practice and can be considered as a criterion for appropriate use. Since prognostic value of performing CCTA in asymptomatic patients is unclear, further prospective studies are needed.

Limitations {#s4e}
-----------

Several limitations should be mentioned. First, this is a single-center study with a medium-size cohort in which the percentage of patients with DM was relatively small. Also, the examinations were performed at a single time point. There were some differences in the baseline characteristics of the two subgroups of patients, like obesity, and medication use, that could have contributed to the higher disease extent observed in patients with DM. Nevertheless, after adjusting for those differences, DM remained an independent predictor of plaque burden and obstructive CAD. Since patients referred for CCTA were suffering from atypical chest pain, but had no history of clinically diagnosed CAD, a potential referral bias has to be taken into account. In addition, limitations of CCTA in general should be mentioned; the presence of ischemia cannot be determined on CCTA, and abnormal CCTA findings should ideally be combined with functional data.

Conclusions {#s5}
===========

Although the prevalence of CAD in patients with atypical chest pain and DM did not differ from that in non-DM, patients with DM with CAD had more advanced CAD than patients without DM. They showed more affected coronary segments and more obstructive CAD than patients without DM; the latter especially in women with DM. Duration of DM (\>5 years), in our study population, was not associated with more obstructive coronary disease or a different plaque morphology, although more distal disease was present.
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